Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
$653.94-0.44%
报价 2026-11-13
市值
$18.29B
EV
$18.39B
PE (TTM)
36.9x
预期 PE (FY2026)
35.8x
52 周区间距高点 -5.6%
$393.42$692.68
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 18.04 → 19.70（1.1x） | 33.2 |
| FY+32028-12 | 1.2x | 18.04 → 22.04（1.2x） | 29.7 |
毛利率 29% · TTM 收入 $2838M · 基数 EPS 18.04（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| MEDPMedpace Holdings, Inc. | $18.29B | -0.4% | +13.5% | 31.3% | 36.9x | 28.6x | 28.4x | |
| WATWaters Corporation | $45.24B | -0.4% | +105.3% | 58.9% | 28.0x | 18.3x | 155.1x | 高增长 |
| CNCCentene Corporation | $35.28B | +1.4% | +3.4% | 17.5% | 23.8x | 7.9x | 8.8x | Cheap |
| ILMNIllumina, Inc. | $31.3B | -1.2% | +7.6% | 66.4% | 49.5x | 30.8x | 43.1x | |
| WSTWest Pharmaceutical Services, Inc. | $29.01B | +1.2% | +11.6% | 39.7% | 45.5x | 29.2x | 62.7x | |
| DGXQuest Diagnostics Incorporated | $28.56B | -0.0% | +10.0% | 33.7% | 24.3x | 15.6x | 21.0x | GARP |
| THCTenet Healthcare Corporation | $22.76B | -0.3% | +4.9% | 62.5% | 8.4x | 5.7x | 7.0x | Cheap |
| ICLRICON Public Limited Company | $14.58B | -2.9% | +1.6% | 19.6% | 34.7x | 13.4x | 12.2x | |
| SNNSmith & Nephew plc | $13.09B | +0.9% | – | 68% | 22.0x | 10.3x | – | |
| 同行中位数 | – | – | +7.6% | 49.3% | 26.1x | 14.5x | 21.0x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $716M | $707.3M | $706.6M | $708.5M | $659.9M | $603.3M | $558.6M | $536.6M |
| Gross Margin | 31.3% | 28.5% | 27.8% | 29% | 29.8% | 29.8% | 31.9% | 33.2% |
| Operating Margin | 23.1% | 20.8% | 20% | 21.6% | 21.5% | 20.9% | 20.3% | 23.4% |
| Net Income | $137.5M | $121.4M | $123.9M | $135.1M | $111.1M | $90.3M | $114.6M | $117M |
| Diluted EPS | 4.84 | 4.25 | 4.28 | 4.67 | 3.87 | 3.1 | 3.67 | 3.67 |
| Operating Cash Flow | $216.6M | $162M | $151.8M | $192.7M | $246.2M | $148.5M | $125.8M | $190.7M |
研究材料
电话会纪要摘要
暂无纪要摘要。